News | Heart Valve Technology | November 02, 2016

Medtronic Harmony Transcatheter Pulmonary Valve Demonstrates Positive Early Clinical Outcomes at One Year

FDA approves IDE study initiation following positive results from first-of-its-kind early feasibility study presented at TCT

Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016

November 2, 2016 — Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early feasibility study, showing improved hemodynamics from baseline and consistent valve performance at one year. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, the positive new data from the first-of-its-kind early feasibility study led the U.S. Food and Drug Administration (FDA) to also recently approve the initiation of a Pivotal Investigational Device Exemption (IDE) study to evaluate the valve’s safety and effectiveness.

The Harmony TPV was designed in an effort to offer a treatment alternative for patients with congenital heart disease (CHD), specifically the 80 percent of CHD patients born with right ventricular outflow tract anomalies who undergo a surgical repair early in life. For these patients, the Harmony TPV provides a less invasive option to restore normal valve function later in life. The minimally invasive TPV therapy builds off of the Melody TPV technology.

“These outcomes are promising indicators that this technology can help patients who experience severe pulmonary regurgitation after repair of complex congenital heart disease,” said Lee N. Benson, M.D., professor of pediatrics at the University of Toronto and director of the Cardiac Diagnostic and Interventional Unit at The Hospital for Sick Children in Toronto, Canada. “We look forward to further evaluating the clinical performance of the Harmony TPV in future studies and providing this growing patient population with a less invasive option to address pulmonary regurgitation, which can be adapted to different outflow tract morphologies,” added Benson, who also presented the data at the meeting.

Patients enrolled in the Harmony TPV early feasibility study who were followed out to one year (N=18) experienced statistically significant improvements in hemodynamics, including RV end diastolic volume from 280.4 ± 74.0ml pre-implant to 195.1 ± 57.9 at one year (N=12, p= 0.001). Mean gradients were consistent and stable at one-year follow up and there were no clinically significant paravalvular leaks.

The Harmony TPV is available for investigational use only.

For more information: www.medtronic.com


Related Content

News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
Subscribe Now